Interferon-α activates interleukin-1 receptor-associated kinase 1 to induce regulatory T-cell apoptosis in patients with systemic lupus erythematosus.
Mingfang LiDatang YuYu WangNa LuoGuangming HanBin YangPublished in: The Journal of dermatology (2021)
Impaired regulatory T-cell (Treg) responses and upregulated interleukin-1 receptor-associated kinase 1 (IRAK1) expression are associated with the development of human systemic lupus erythematosus (SLE). Here, we show that the levels of upregulated IRAK1 expression in circulating Tregs are correlated with the percentages of apoptotic Tregs, Systemic Lupus Erythematosus Disease Activity Index scores, and serum complement C3 levels in SLE patients. High levels of plasma interferon (IFN)-α in SLE patients induced IRAK1 phosphorylation to trigger Treg apoptosis, which was mitigated by IRAK1 inhibitor (IRAK-Inh) treatment. Bioinformatics indicated that IRAK1 activation was related to the IFN-α/β and mitogen-activated protein kinase (MAPK) signaling in Tregs and IFN-α treatment induced the p38 and MAPK/ERK kinase 3/6 phosphorylation, which was attenuated by IRAK-Inh in Tregs. Treatment with IRAK-Inh effectively alleviated renal injury and promoted the survival of lupus-prone B6.MRL-Faslpr /Nju mice. Therefore, IFN-α induced IRAK1 activation to promote Treg apoptosis, contributing to the pathogenesis of SLE and IFN-α/IRAK1 may be therapeutic targets for SLE.
Keyphrases
- systemic lupus erythematosus
- disease activity
- dendritic cells
- rheumatoid arthritis
- oxidative stress
- rheumatoid arthritis patients
- ankylosing spondylitis
- immune response
- diabetic rats
- end stage renal disease
- protein kinase
- signaling pathway
- high glucose
- endothelial cells
- juvenile idiopathic arthritis
- newly diagnosed
- ejection fraction
- poor prognosis
- endoplasmic reticulum stress
- prognostic factors
- binding protein
- drug induced
- cell cycle arrest
- metabolic syndrome
- type diabetes